Mint Tower Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mint Tower Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,800	Closed	-$1.77M	–	395
2021 Q4	$1.77M	Buy	+2,800	New	+$1.72M	0.23%	93
2019 Q3	–	Sell	-7,500	Closed	-$2.35M	–	240
2019 Q2	$2.35M	Sell	7,500 -5,900	-44%	-$1.96M	0.26%	94
2019 Q1	$5.5M	Buy	+13,400	New	+$5.52M	0.53%	30

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mint Tower Capital Management's REGN Position: Q1 2022 in Review

Mint Tower Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 59 shares — an estimated $37K sold.

Mint Tower Capital Management first reported a position in REGN in Q1 2019 and held it in 3 quarters. The position peaked at $1.51M in Q2 2019. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Mint Tower Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Mint Tower Capital Management sold 59 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $37K.
Mint Tower Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 3 quarters.
Mint Tower Capital Management's Regeneron Pharmaceuticals position peaked at $1.51M in Q2 2019.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Mint Tower Capital Management's 13F filing for Q1 2022, filed 29 Apr 2022.